- Investing Ideas
- Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
3
1 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
3 companies
Sandoz Group
Market Cap: CHF 28.8b
Develops, manufactures, and markets generic and biosimilars worldwide.
New
SDZ
CHF 66.62
7D
4.1%
1Y
110.2%
Bachem Holding
Market Cap: CHF 5.0b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 66.35
7D
-0.7%
1Y
42.0%
Tecan Group
Market Cap: CHF 1.7b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 134.90
7D
-0.4%
1Y
-6.3%